Retirement Systems of Alabama Buys 25,967 Shares of Lantheus Holdings, Inc. $LNTH

Retirement Systems of Alabama grew its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 16.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 186,010 shares of the medical equipment provider’s stock after purchasing an additional 25,967 shares during the quarter. Retirement Systems of Alabama owned 0.28% of Lantheus worth $18,514,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Western Wealth Management LLC bought a new stake in shares of Lantheus in the 1st quarter worth approximately $25,000. Bessemer Group Inc. boosted its holdings in Lantheus by 221.2% during the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 354 shares in the last quarter. USA Financial Formulas bought a new stake in Lantheus during the third quarter worth approximately $41,000. Allworth Financial LP acquired a new position in Lantheus in the second quarter worth approximately $49,000. Finally, Farther Finance Advisors LLC grew its position in Lantheus by 122.9% in the third quarter. Farther Finance Advisors LLC now owns 555 shares of the medical equipment provider’s stock worth $55,000 after buying an additional 306 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

LNTH stock opened at $101.60 on Thursday. The firm has a 50 day simple moving average of $100.30 and a 200 day simple moving average of $92.57. Lantheus Holdings, Inc. has a 52 week low of $51.47 and a 52 week high of $111.86. The stock has a market cap of $6.64 billion, a P/E ratio of 25.02 and a beta of 0.01. The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.06 and a current ratio of 3.25.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, November 5th. The medical equipment provider reported $1.68 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.45. Lantheus had a net margin of 17.28% and a return on equity of 29.26%. The firm had revenue of $389.91 million for the quarter, compared to analyst estimates of $355.74 million. During the same quarter in the prior year, the business earned $1.27 EPS. The company’s revenue for the quarter was up 1.5% compared to the same quarter last year. Research analysts anticipate that Lantheus Holdings, Inc. will post 4.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

LNTH has been the subject of several analyst reports. Truist Financial downgraded Lantheus from a “buy” rating to a “hold” rating and reduced their target price for the company from $125.00 to $102.50 in a report on Monday, August 3rd. Weiss Ratings lowered Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, October 15th. Leerink Partners set a $102.50 price target on Lantheus in a research note on Monday, August 3rd. William Blair set a $102.50 target price on shares of Lantheus in a report on Monday, August 3rd. Finally, TD Cowen cut shares of Lantheus from a “buy” rating to a “hold” rating and decreased their target price for the stock from $110.00 to $102.50 in a report on Monday, August 3rd. Three analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat, Lantheus presently has an average rating of “Hold” and a consensus price target of $107.44.

Lantheus Profile

Lantheus Holdings is a radiopharmaceutical and medical imaging company that develops, manufactures, and commercializes products used to diagnose and manage disease. Its offerings support imaging across several areas of medicine, including oncology and cardiology. The company’s products include Pylarify, a positron emission tomography (PET) imaging agent used to detect prostate cancer; Definity, an ultrasound contrast agent used in cardiac imaging; and TechneLite, a generator that supplies technetium-99m for diagnostic imaging procedures.